The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Open accessThe DOI matches its Crossref record; 335 of the 339 references it cites were found in a registry or an index.
Abstract
Transporter-mediated drug resistance is a major obstacle in anticancer drug delivery and a key reason for cancer drug therapy failure. Membrane solute carrier (SLC) transporters play a crucial role in the cellular uptake of drugs. The expression and function of the SLC transporters can be down-regulated in cancer cells, which limits the uptake of drugs into the tumor cells, resulting in the inefficiency of the drug therapy. In this review, we summarize the current understanding of low-SLC-transporter-expression-mediated drug resistance in different types of cancers. Recent advances in SLC-transporter-targeting strategies include the development of transporter-utilizing prodrugs and nanocarriers and the modulation of SLC transporter expression in cancer cells. These strategies will play an important role in the future development of anticancer drug therapies by enabling the efficient delivery of drugs into cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–335 of 335
SHENNAN, D. B., Thomson, J., Gow, I. F., Travers, M. T., & BARBER, M. C. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2004.05.008 · Cited by 80
Casanello, P. C., Torres, A., Sanhueza, F., González, M., Farías, M., Gallardo, V., Pastor‐Anglada, M., Martín, R. S., & Sobrevía, L. (2005) · Circulation Research · doi:10.1161/01.res.0000172568.49367.f8 · Cited by 79
Brouwer, K. L. R., Evers, R., Hayden, E. R., Hu, S., Li, C. Y., zu Schwabedissen, H. E. M., Neuhoff, S., Oswald, S., Piquette‐Miller, M., Saran, C., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2605 · Cited by 78
Role of organic cation transporters in drug-induced toxicity
Ciarimboli, G. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.547474 · Cited by 78
L-Type Amino Acid Transporter-1 Overexpression and Melphalan Sensitivity in Barrett's Adenocarcinoma
Lin, J., Raoof, D. A., Thomas, D. G., Greenson, J. K., Giordano, T. J., Robinson, G. S., Bourner, M. J., Bauer, C. T., Orringer, M. B., & Beer, D. G. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80054-x · Cited by 77
Bhunia, S., Vangala, V., Bhattacharya, D., Ravuri, H. G., Kuncha, M., Chakravarty, S., Sistla, R., & Chaudhuri, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00569 · Cited by 77
Regulation of Reduced Folate Carrier (RFC) by Vitamin D Receptor at the Blood-Brain Barrier
Alam, C., Hoque, M. T., Finnell, R. H., Goldman, I. D., & Bendayan, R. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00572 · Cited by 75
Yanagisawa, N., Ichinoe, M., Mikami, T., Nakada, N., Hana, K., Koizumi, W., Endou, H., & Okayasu, I. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-200826 · Cited by 75
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
Huang, K. M., Leblanc, A. F., Uddin, M. E., Kim, J., Chen, M., Eisenmann, E. D., Gibson, A. A., Li, Y., Hong, K. W., DiGiacomo, D. F., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136796 · Cited by 75
Anderson, C. M., Xiong, W., Young, J. D., Cass, C. E., & Parkinson, F. E. (1996) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00244-6 · Cited by 73
Shi, C., Wu, B. J., Chu, G. C.-Y., Li, Q., Wang, R., Zhang, C., Zhang, Y., Kim, H. L., Wang, J., Zhau, H. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2464 · Cited by 72
Lopes, C., Pereira, C., & Medeiros, R. (2021) · Cancers · doi:10.3390/cancers13020203 · Cited by 72
Pochini, L., Scalise, M., Galluccio, M., Pani, G., Siminovitch, K. A., & Indiveri, C. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.12.014 · Cited by 71
Minuesa, G., Purcet, S., Erkizia, I., Molina‐Arcas, M., Bofill, M., Izquierdo‐Useros, N., Casado, F. J., Clotet, B., Pastor‐Anglada, M., & Martínez‐Picado, J. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131482 · Cited by 70
Hijacking Solute Carriers for Proton-Coupled Drug Transport
Anderson, C. M. H., & Thwaites, D. T. (2010) · Physiology · doi:10.1152/physiol.00027.2010 · Cited by 69
Mohelníková-Duchoňová, B., Brynychová, V., Hlaváč, V., Kočík, M., Oliverius, M., Hlavsa, J., Honsová, E., Mazanec, J., Kala, Z., Melichar, B., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2246-2 · Cited by 69
Expression Profile and Functional Activity of Peptide Transporters in Prostate Cancer Cells
Tai, W., Chen, Z., & Cheng, K. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300364k · Cited by 69
High expression of L-type amino acid transporter 1 in infiltrating glioma cells
Nawashiro, H., Otani, N., Uozumi, Y., Ooigawa, H., Toyooka, T., Suzuki, T., Katoh, H., Tsuzuki, N., Ohnuki, A., Shima, K., et al. (2005) · Brain Tumor Pathology · doi:10.1007/s10014-005-0188-z · Cited by 68
P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate
Jia, Y., Liu, Z., Wang, C., Meng, Q., Huo, X., Liu, Q., Sun, H., Sun, P., Yang, X., Ma, X., et al. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.06.030 · Cited by 67
Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer
Girisa, S., Henamayee, S., Parama, D., Rana, V., Dutta, U., & Kunnumakkara, A. B. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00035-2 · Cited by 66
Billington, S. F., Ray, A. S., Salphati, L., Xiao, G., Chu, X., Humphreys, W. G., Liao, M., Lee, C. A., Mathias, A. A., Hop, C. E. C. A., et al. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.077289 · Cited by 66
Lancaster, C. S., Sprowl, J. A., Walker, A. L., Hu, S., Gibson, A. A., & Sparreboom, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0926 · Cited by 66
Sierra, E. E., Brigle, K. E., Spinella, M. J., & Goldman, I. D. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00730-7 · Cited by 66
Identification of drug transporters contributing to oxaliplatin‐induced peripheral neuropathy
Fujita, S., Hirota, T., Sakiyama, R., Baba, M., & Ieiri, I. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14607 · Cited by 65
Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
Hu, C., Lancaster, C. S., Zuo, Z., Hu, S., Chen, Z., Rubnitz, J. E., Baker, S. D., & Sparreboom, A. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0980 · Cited by 65
Sikder, M. O. F., Yang, S., Ganapathy, V., & Bhutia, Y. D. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0164-7 · Cited by 64
Lang, T. T., Selner, M., Young, J. D., & Cass, C. E. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.5.1143 · Cited by 64
Afonso, J., Pinto, T., Simoes‐Sousa, S., Schmitt, F. C., Longatto‐Filho, A., Pinheiro, C. M., Marques, H., & Baltazar, F. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00426-2 · Cited by 63
Dahlin, A., Geier, E., Stocker, S. L., Cropp, C. D., Grigorenko, E., Bloomer, M., Siegenthaler, J., Xu, L., Basile, A. S., Tang-Liu, D. D.-S., et al. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300429e · Cited by 61
Characterization of the human MATE2 proton-coupled polyspecific organic cation exporter
Komatsu, T., Hiasa, M., Miyaji, T., Kanamoto, T., Matsumoto, T., Otsuka, M., Moriyama, Y., & Omote, H. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.03.005 · Cited by 61
Kim, H. K., Lee, I.-K., Bang, H., Kim, H. C., Lee, W. Y., Yun, S. H., Lee, J., Lee, S. J., Park, Y. S., Kim, K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0535 · Cited by 60
Tsujie, M., Nakamori, S., Nakahira, S., Takahashi, Y. K., Hayashi, N., Okami, J., Nagano, H., Dono, K., Umeshita, K., Sakon, M., et al. (2007) · PubMed · Cited by 60
Wang, C., Uray, I. P., Mazumdar, A., Mayer, J. A., & Brown, P. H. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1925-0 · Cited by 59
Sundaram, M., Yao, S. Y. M., Ng, A. M. L., Cass, C. E., Baldwin, S. A., & Young, J. D. (2001) · Biochemistry · doi:10.1021/bi0101805 · Cited by 59
Swift, B., Nebot, N., Lee, J. K., Han, T. K., Proctor, W. R., Thakker, D. R., Lang, D. H., Radtke, M., Gnoth, M. J., & Brouwer, K. L. R. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048181 · Cited by 59
LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
Lin, Z., Xia, S., Liang, Y., Ji, L., Pan, Y., Shi, J., Wan, Z., Tao, L., Chen, J., Lin, C., et al. (2020) · Theranostics · doi:10.7150/thno.45158 · Cited by 59
Amino Acid Transporters as Disease Modifiers and Drug Targets
Bröer, S. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218755629 · Cited by 58
Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography
Bauer, M., Matsuda, A., Wulkersdorfer, B., Philippe, C., Traxl, A., Özvegy‐Laczka, C., Stanek, J., Nics, L., Klebermass, E., Poschner, S., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.888 · Cited by 58
OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues
Drenberg, C. D., Gibson, A. A., Pounds, S. B., Shi, L., Rhinehart, D. P., Li, L., Hu, S., Du, G., Nies, A. T., Schwab, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2548 · Cited by 58
Murray, M. T., & Zhou, F. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13785 · Cited by 57
Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
Zhou, M., Wang, D., Li, X., Cao, Y., Yi, C., Ocansey, D. K. W., Zhou, Y., & Mao, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1016836 · Cited by 56
Garrett, Q., Xu, S., Simmons, P. A., Vehige, J., Flanagan, J. L., & Willcox, M. D. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1528 · Cited by 55
Hays, A. L., Apte, U. M., & Hagenbuch, B. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0962-7 · Cited by 55
Sutherland, R., Meeson, A. P., & Lowes, S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09879-6 · Cited by 55
Fink, M. A., Paland, H., Herzog, S., Grube, M., Vogelgesang, S., Weitmann, K., Bialke, A., Hoffmann, W. U., Rauch, B. H., Schroeder, H. W. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2380 · Cited by 55
Urquhart, B. L., Gregor, J. C., Chande, N., Knauer, M. J., Tirona, R. G., & Kim, R. B. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00224.2009 · Cited by 54
Xiong, F., Zhu, Z., Chen, X., Hua, X., Shan, X., Zhang, Y., & Gu, N. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0653-9 · Cited by 54
α‐Emitting cancer therapy using 211At‐AAMT targeting LAT1
Kaneda‐Nakashima, K., Zhang, Z., Manabe, Y., Shimoyama, A., Kabayama, K., Watabe, T., Kanai, Y., Ooe, K., Toyoshima, A., Shirakami, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14761 · Cited by 54
Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation
Hayden, E. R., Chen, M., Pasquariello, K. Z., Gibson, A. A., Petti, J. J., Shen, S., Qu, J., Ong, S. S., Chen, T., Jin, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0023 · Cited by 54
Guillén‐Gómez, E., Calbet, M., Casado, J. F., de Lecea, L., Soriano, E., Pastor‐Anglada, M., & Burgaya, F. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02545.x · Cited by 54
Protein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression
Mayati, A., Moreau, A., Vée, M. L., Stieger, B., Denizot, C., Parmentier, Y., & Fardel, O. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040764 · Cited by 54
Overcoming treatment resistance in cancer: Current understanding and tactics
Wu, G. J., Wilson, G., George, J., Liddle, C., Hebbard, L., & Qiao, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.018 · Cited by 52
Sweet, R. L., Paul, A. M., & Zastre, J. A. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.11.13444 · Cited by 52
Lautem, A., Heise, M., GRÄSEL, A., Hoppe‐Lotichius, M., Weiler, N., Foltys, D. B., Knapstein, J., Schattenberg, J. M., Schad, A., Zimmermann, A., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1840 · Cited by 52
Epigenetic Regulation of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines
Imai, S., Kikuchi, R., Tsuruya, Y., Naoi, S., Nishida, S., Kusuhara, H., & Sugiyama, Y. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1117-1 · Cited by 51
Luo, Q., Gong, P., Sun, M., Kou, L., Ganapathy, V., Jing, Y., He, Z., & Sun, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.031 · Cited by 50
Prognostic significance of monocarboxylate transporter expression in oral cavity tumors
Simoes‐Sousa, S., Granja, S., Pinheiro, C. M., Fernandes, D., Longatto‐Filho, A., Laus, A. C., Alves, C. D. C., Peñaranda, J. M. S., Pérez‐Sayáns, M., Carvalho, A. L., et al. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1188239 · Cited by 50
Distribution of organic anion transporters NaDC3 and OAT1-3 along the human nephron
Breljak, D., Ljubojević, M., Hagos, Y., Micek, V., Balen, D., Vrhovac, I., Brzica, H., Karaica, D., Radović, N., Kraus, O., et al. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00113.2016 · Cited by 50
Lee, W., Ha, J.-M., & Sugiyama, Y. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.009132 · Cited by 49
Wada, E., Koyanagi, S., Kusunose, N., Akamine, T., Masui, H., Hashimoto, H., Matsunaga, N., & Ohdo, S. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094979 · Cited by 49
Winter, S., Fisel, P., Büttner, F., Rausch, S., D’Amico, D., Hennenlotter, J., Kruck, S., Nies, A. T., Stenzl, A., Junker, K., et al. (2016) · Scientific Reports · doi:10.1038/srep29930 · Cited by 49
Cation coupling properties of human concentrative nucleoside transporters hCNT1, hCNT2 and hCNT3
Smith, K. M., Slugoski, M. D., Cass, C. E., Baldwin, S. A., Karpinski, E., & Young, J. D. (2006) · Molecular Membrane Biology · doi:10.1080/09687860600942534 · Cited by 49
The Role of the Aryl Hydrocarbon Receptor (AhR) and Its Ligands in Breast Cancer
Safe, S. H., & Zhang, L. (2022) · Cancers · doi:10.3390/cancers14225574 · Cited by 49
Daskalow, K., Pfander, D., Weichert, W., Rohwer, N., Thelen, A., Neuhaus, P., Jonas, S., Wiedenmann, B., Benckert, C., & Cramer, T. (2009) · Histochemistry and Cell Biology · doi:10.1007/s00418-009-0590-4 · Cited by 48
Cysteine is not a substrate but a specific modulator of human ASCT2 (SLC1A5) transporter
Scalise, M., Pochini, L., Pingitore, P., Hedfalk, K., & Indiveri, C. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.011 · Cited by 48
Namisaki, T., Schaeffeler, E., Fukui, H., Yoshiji, H., Nakajima, Y., Fritz, P., Schwab, M. G., & Nies, A. T. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059832 · Cited by 46
Wang, C., Wu, J.-M., Wang, Z.-J., Yang, Z., Li, Z., Deng, H., Li, L., Peng, X., & Feng, M. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.035 · Cited by 45
Iwaki, M., Shimada, H., Irino, Y., Take, M., & Egashira, S. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00970 · Cited by 45
DNA Methylation Profiles of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines
Ichihara, S., Kikuchi, R., Kusuhara, H., Imai, S., Maeda, K., & Sugiyama, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0064-3 · Cited by 44
The cell biology of ion pumps: sorting and regulation
Dunbar, L. A., & Caplan, M. J. (2000) · European Journal of Cell Biology · doi:10.1078/0171-9335-00079 · Cited by 44
Kilari, D., Iczkowski, K. A., Pandya, C. J., Robin, A. J., Messing, E. M., Guancial, E. A., & Kim, E. S. (2016) · PubMed · Cited by 44
Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-d-g1ucose modified SPIOs
Shan, X. H., Hu, H., Xiong, F., Gu, N., Geng, X. D., Zhu, W., Lin, J., & Wang, Y. F. (2011) · European Journal of Radiology · doi:10.1016/j.ejrad.2011.03.013 · Cited by 43
Luo, Q., Yang, B., Tao, W., Li, J., Kou, L., Lian, H., Che, X., He, Z., & Sun, J. (2016) · Biomaterials Science · doi:10.1039/c6bm00788k · Cited by 43
Regulation ofOCT2transcriptional repression by histone acetylation in renal cell carcinoma
Zhu, Q., Yu, L., Qin, Z., Chen, L., Hu, H., Zheng, X., & Zeng, S. (2019) · Epigenetics · doi:10.1080/15592294.2019.1615354 · Cited by 42
Functional influence ofN-glycosylation in OCT2-mediated tetraethylammonium transport
Pelis, R. M., Suhre, W. B., & Wright, S. H. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00462.2005 · Cited by 42
Briasoulis, E. C., Kounnis, V., Loakim, Svoboda, M., Tzakos, A. G., Sainis, I., Thalhammer, T., & Steiner, G. (2011) · OncoTargets and Therapy · doi:10.2147/ott.s16706 · Cited by 40
High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy
Terakawa, T., Katsuta, E., Yan, L., Turaga, N., McDonald, K.-A., Fujisawa, M., Guru, K. A., & Takabe, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24453 · Cited by 40
Zhou, P., Liang, X., Zhou, C., Qin, J., Hou, C., Zhu, Z., Zhang, W., Wang, S., & Zhong, D. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01225g · Cited by 39
Du, Y., Tian, C., Wang, M., Huang, D., Wei, W., Liu, Y., Li, L., Sun, B., Kou, L., Kan, Q., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1480675 · Cited by 39
Kou, L., Huang, H., Lin, X., Jiang, X., Wang, Y., Luo, Q., Sun, J., Yao, Q., Ganapathy, V., & Chen, R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1723544 · Cited by 39
Vée, M. L., Jouan, E., Stieger, B., Lecureur, V., & Fardel, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121232 · Cited by 39
Molecular Basis of Nucleobase Transport Systems in Mammals
Inoue, K. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00374 · Cited by 38
Thompson, B. R., Shi, J., Zhu, H.-J., & Smith, D. E. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114127 · Cited by 37
Zhu, P., Zhou, K., Lu, S., Bai, Y., Qi, R., & Zhang, S. (2020) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-019-00535-5 · Cited by 36
Vée, M. L., Jouan, E., Stieger, B., & Fardel, O. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.01.005 · Cited by 36
Windt, T., Tóth, S., Patik, I., Sessler, J., Kucsma, N., Szepesi, Á., Zdrazil, B., Özvegy‐Laczka, C., & Szakács, G. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02417-6 · Cited by 36
Transcriptional Regulation of Solute Carrier Drug Transporters
Zhou, S., & Shu, Y. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000704 · Cited by 36
Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery
Singh, V. K., & Subudhi, B. B. (2016) · Drug Delivery · doi:10.3109/10717544.2014.984369 · Cited by 36
Identification of liver metastasis-associated genes in human colon carcinoma by mRNA profiling
Liu, J., Wang, D., Zhang, C., Zhang, Z., Chen, X., Lian, J., Liu, J., Wang, G., Yuan, W., Sun, Z., et al. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.06.08 · Cited by 34
Lopes‐Coelho, F., Nunes, C., Gouveia-Fernandes, S., Rosas, R., SILVA, F. A. B. N. D., Gameiro, P., Carvalho, T., da Silva, M. G., Cabeçadas, J., Dias, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20294 · Cited by 34
Gong, Y., Wu, X., Wang, T., Zhao, J., Liu, X., Yao, Z., Zhang, Q., & Xu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17117 · Cited by 33
Marada, V. V. V. R., Flörl, S., Kühne, A., Müller, J., Burckhardt, G., & Hagos, Y. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.11.002 · Cited by 32
Tao, W., Zhao, D., Sun, M., Wang, Z., Lin, B., Bao, Y. J., Li, Y., He, Z., Sun, Y. H., & Sun, J. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.02.033 · Cited by 32
Gnana‐Prakasam, J. P., Reddy, S. K., Veeranan‐Karmegam, R., Smith, S. B., Martin, P. M., & Ganapathy, V. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8264 · Cited by 31
Jiang, X., Xin, H., Gu, J., Du, F., Feng, C., Xie, Y., & Fang, X. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23928 · Cited by 31
Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1
Chen, M., Neul, C., Schaeffeler, E., Frisch, F., Winter, S., Schwab, M. G., Koepsell, H., Hu, S., Laufer, S., Baker, S. D., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1588 · Cited by 30
Structural basis for substrate specificity of heteromeric transporters of neutral amino acids
Rodríguez, C. F., Escudero-Bravo, P., Díaz, L., Bartoccioni, P., García‐Martín, C., Gilabert, J. G., Boskovic, J., Guallar, V., Errasti‐Murugarren, E., Llorca, Ó., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113573118 · Cited by 30
Alam, K., Farasyn, T., Crowe, A., Ding, K., & Yue, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186924 · Cited by 30
Wang, Y., Zhu, Q., Hu, H., Zhu, H., Yang, B., He, Q., Yu, L., & Zeng, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114546 · Cited by 29
Hosoya, K., Kyoko, H., Toyooka, N., Kato, A., Orihashi, M., Tomi, M., & Tachikawa, M. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.2126 · Cited by 29
Huang, C., Chen, H., Lin, T.-Y., Lin, A., & Lii, C. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.01.026 · Cited by 27
Huang, X., Wang, B., Chen, R., Zhong, S., Gao, F., Zhang, Y., Niu, Y., Li, C., & Shi, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.583146 · Cited by 27
Hong, S., Fang, Z., Jung, H.-Y., Yoon, J., Hong, S., & Maeng, H. (2018) · Molecules · doi:10.3390/molecules23102608 · Cited by 27
Melphalan concentration dependent plasma protein binding in healthy humans and rats
Greig, N. H., Sweeney, D. J., & Рапопорт, С. И. (1987) · European Journal of Clinical Pharmacology · doi:10.1007/bf00542192 · Cited by 26
Organic Anion Transporters (OAT) and Other SLC22 Transporters in Progression of Renal Cell Carcinoma
Whisenant, T. C., & Nigám, S. K. (2022) · Cancers · doi:10.3390/cancers14194772 · Cited by 26
Vasilogianni, A., Al‐Majdoub, Z. M., Achour, B., Peters, S. A., Barber, J., & Rostami‐Hodjegan, A. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2633 · Cited by 24
Role of the constitutive androstane receptor (CAR) in human liver cancer
Bae, S. D. W., Nguyen, R., Qiao, L., & George, J. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188516 · Cited by 24
Correlation of anti-tumour drug resistance with epigenetic regulation
Hayashi, T., & Konishi, I. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01183-y · Cited by 24
PEPT1 is essential for the growth of pancreatic cancer cells: a viable drug target
Schniers, B. K., Rajasekaran, D., Korać, K., Sniegowski, T., Ganapathy, V., & Bhutia, Y. D. (2021) · Biochemical Journal · doi:10.1042/bcj20210377 · Cited by 23
Regulatory Role of Testosterone in Organic Cation Transport: in Vivo and in Vitro Studies
Meetam, P., Srimaroeng, C., Soodvilai, S., & Chatsudthipong, V. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.982 · Cited by 23
Odin, E., Sondén, A., Gustavsson, B. G., Carlsson, G. U., & Wettergren, Y. (2015) · Molecular Medicine · doi:10.2119/molmed.2014.00192 · Cited by 23
Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen
Gao, C., Pu, Z., He, C., Liang, D., Jia, Y., Yuan, X., Wang, G., & Xie, H. (2017) · Oncology Reports · doi:10.3892/or.2017.5727 · Cited by 22
Korkuć, P., & Walther, D. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25200 · Cited by 21
Hsu, C., Lin, P., Chang, J., Lin, H., Li, S.-H., Lin, S.-F., & Yang, M. (2017) · Oncotarget · doi:10.18632/oncotarget.20637 · Cited by 21
Ohshima, Y., Suzuki, H. Y., Hanaoka, H., Sasaki, I., Watanabe, S., Haba, H., Arano, Y., Tsushima, Y., & Ishioka, N. S. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.08.003 · Cited by 21
Pocasap, P., Weerapreeyakul, N., Timonen, J. M., Järvinen, J., Leppänen, J., Kärkkäinen, J., & Rautio, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062132 · Cited by 21
Searching for Constitutive Androstane Receptor Modulators
Honkakoski, P. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000482 · Cited by 20
Fan, Y., & You, G. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118653 · Cited by 20
Wang, L., Giannoudis, A., Austin, G. M., & Clark, R. E. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.05.013 · Cited by 19
Haberkorn, B., Oswald, S., Kehl, N., Gessner, A., Taudte, R. V., Dobert, J. P., Zunke, F., Fromm, M. F., & König, J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.122.000539 · Cited by 19
MYCNamplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma
Lau, D. T., Flemming, C. L., Gherardi, S., Perini, G., Oberthuer, A., Fischer, M., Juraeva, D., Brors, B., Xue, C., Norris, M. D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3732 · Cited by 19
Mahringer, A., Bernd, A., Miller, D. S., & Fricker, G. (2019) · Biological Chemistry · doi:10.1515/hsz-2018-0425 · Cited by 19
Self-citationTang, T., Wang, G., Liu, S., Zhang, Z., Liu, C., Li, F., Liu, X., Meng, L., Yang, H., Li, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80152-0 · Cited by 18
Chen, S., Li, K., Jiang, J., Wang, X., Chai, Y., Zhang, C., Deng, Q., Shuai, L., Feng, K., Ma, K., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01891-y · Cited by 18
Austin, G. M., Holcroft, A. K., Rinne, N., Wang, L., & Clark, R. E. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12409 · Cited by 17
Zhang, X., Zhang, D., Huang, L., Li, G., Chen, L., Ma, J., Li, M., Wei, M., Zhou, W., Zhou, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00944 · Cited by 16
Shimada, T., Nakanishi, T., Tajima, H., Yamazaki, M., Yokono, R., Takabayashi, M., Shimada, T., Sawamoto, K., Miyamoto, K., Kitagawa, H., et al. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24498 · Cited by 15
Wang, Z., Lin, X., Chi, D., Xu, Z., Lin, G., Liu, H., Sun, J., He, Z., & Wang, Y. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119680 · Cited by 15
Cooper, E., Woolf, Z., Swanson, M. E. V., Correia, J. A., Schweder, P. M., Mee, E. T., Heppner, P. A., Turner, C. P., Faull, R. L. M., Scotter, E. L., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac166 · Cited by 15
Wen, J., & Zhao, M. (2021) · Disease Markers · doi:10.1155/2021/9711179 · Cited by 15
Gu, J., Wang, L., Li, T., Tang, S., Wang, Y., Zhang, W., & Jiang, X. (2019) · Oncology Reports · doi:10.3892/or.2019.7267 · Cited by 13
Liver Receptor Homolog-1 Regulates Organic Anion Transporter 2 and Docetaxel Pharmacokinetics
Yu, F., Zhang, T., Guo, L., & Wu, B. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.080895 · Cited by 10
Transcriptional regulation of breast cancer resistance protein
Wu, X., Peng, S., & Huang, Q. (2012) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2012.01529 · Cited by 9
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.389 · Cited by 5
SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma
Hlaváč, V., Václavíková, R., Brynychová, V., Dvořák, P., Elsnerová, K., Koževnikovová, R., Rauš, K., Kopečková, K., Měšťáková, S., Vrána, D., et al. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00506-2 · Cited by 2
Cited by
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
Hallmarks of cancer resistance
Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · iScience · doi:10.1016/j.isci.2024.109979 · Cited by 149
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Reduced drug influx is a common mechanism of resistance, often resulting from decreased expression of transporters responsible for drug uptake, such as membrane solute carrier (SLC) family proteins [43].”
Pu, J., Yuan, K., Tao, J., Qin, Y., Li, Y., Fu, J., Zhong, L., Zhou, H., Tang, Z., Li, L., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02567-3 · Cited by 77
Barathan, M., Zulpa, A. K., Ng, S. L., Lokanathan, Y., Ng, M. H., & Law, J. X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137470 · Cited by 55
Metadata
- Authors
- Puris, E., Fricker, G., & Gynther, M.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Gynther, Mikko
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-01-21
- Volume
- 15
- Issue
- 2
- Pages
- 364
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9966068
- OpenAlex
- W4317733597
- Cited by
- 58
- References
- 339
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 19 · 2023: 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- solute carrier transporters, anticancer drug delivery, drug resistance, cancer cells, drug uptake, nanocarriers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.